First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple MyelomaPaul G. Richardson,Enrique M. Ocio,Noopur Raje,Tara Gregory,Darrell White,Albert Oriol,Irwindeep Sandhu,Marc-Steffen Raab,Richard LeBlanc,Cesar Rodriguez Valdes,Suzanne Trudel,Ralph Wasch,Aurore Perrot,Nizar J. Bahlis,Zehua Zhou,Manisha Lamba,Michael Amatangelo,Tiziana Civardi,Jessica Katz,Paulo Maciag,Teresa Peluso,Meletios A. DimopoulosBRITISH JOURNAL OF HAEMATOLOGY（2022）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
